

Special Issue

Cepharanthine: Pharmacological Properties and Medical Applications

Message from the Guest Editors

Cepharanthine is a dibenzyl isoquinoline alkaloid extracted from the rhizomes of *Stephania*. It has anti-tumor, anti-inflammatory, anti-oxidation, anti-viral, anti-parasitic, anti-bacterial, bone absorption inhibition, and immune regulation activities. The clinical application of cepharanthine is limited due to its low solubility and low bioavailability. Therefore, further research on its pharmacological properties and medical application can improve the existing deficiencies and promote the application of cepharanthine. This Special Issue will publish studies related to cepharanthine, including the synthesis, metabolism, drug activity, related signaling pathways, pharmacokinetics, toxicology, clinical application and other studies related to cepharanthine, and encourages submissions from all fields of pharmacology, life science and clinical medicine. Topics of special interest include, but are not limited to, anti-tumor, anti-inflammatory, immunomodulatory, epidemiological studies of cepharanthine, and studies related to its pharmacological properties and medical applications in inhibiting bone absorption, treating alopecia, treating snakebite, and regulating signaling pathways.

Guest Editors

Dr. Huahao Fan


Prof. Dr. Yigang Tong

Dr. Guifang Dou

Dr. Chi Song

Deadline for manuscript submissions

closed (30 July 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/131210

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).